Plasminogen activators and their inhibitors in synovial fluids from normal, osteoarthritis, and rheumatoid arthritis knees

Annals of the Rheumatic Diseases

Volumn 55, Issue 4, 1996, Pages 230-236

  Belcher, Carolyn ^a   Fawthrop, Fiona ^a   Bunning, Rowena ^b   Doherty, Michael ^a  

^a NOTTINGHAM CITY HOSPITAL   (United Kingdom)

^b SHEFFIELD HALLAM UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PLASMINOGEN ACTIVATOR; PLASMINOGEN ACTIVATOR INHIBITOR;

ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GEL ELECTROPHORESIS; HUMAN; INFLAMMATION; KNEE; MAJOR CLINICAL STUDY; OSTEOARTHRITIS; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SYNOVIAL FLUID;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ARTHRITIS, RHEUMATOID; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FEMALE; HUMANS; KNEE JOINT; MALE; MIDDLE AGED; OSTEOARTHRITIS; PLASMINOGEN ACTIVATORS; PLASMINOGEN INACTIVATORS; REFERENCE VALUES; SYNOVIAL FLUID;

EID: 0029940075     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.55.4.230     Document Type: Article

References (36)

1. Dano K, Andreason P, Grondahl-Hansen J, Kristensen P, Neilson L S, Skriver L. Plasminogen activators, tissue degradation and cancer. Adv Cancer Res 1985; 44: 139-66.
2. Hart D A, Rehemtulla A. Plasminogen activators and their inhibitors: regulators of extracellular proteolysis and cell function. Comp Biochem Physiol 1988; 90B: 691-708.
3. Fairbairn S, Gilbert R, Ojakian G, Schwimmer R, Quigley J. The extracellular matrix of normal chick embryo fibroblasts: its effect on transformed chick fibroblasts and its proteolytic degradation by transformants. J Cell Biol 1985; 101: 1790-8.
4. Mochan E, Keler T. Plasmin degradation of cartilage proteoglycan. Biochim Biophys Acta 1984; 800: 312-5.
5. Lack C H, Rogers H J. Action of plasmin on cartilage. Nature 1958; 182: 948-9.
6. Pelletier J-P, Martel-Pelletier J, Howell D S, Ghander-Mnaymneh L, Emis J E, Woessner J F Jr. Collagenase and collagenolytic activity in human osteoarthritic cartilage. Arthritis Rheum 1983; 26: 63-8.
7. Collier S, Ghosh P. The role of plasminogen in interleukin-1 mediated cartilage degradation. J Rheumatol 1988; 15: 1129-37.
8. Werb Z, Mainardi C L, Vater C A, Harris E D Jr. Endogenous activators of latent collagenase by rheumatoid synovial cells. Evidence for a role of plasminogen activator. N Engl J Med 1977; 296: 1017-23.
9. Kruithof E K O, Tran-Thang C, Ransjin A, Bachmann F. Demonstration of a fast acting inhibitor of plasminogen activators in human plasma. Blood 1984; 64: 907-13.
10. Knudsen B, Harpel P C, Nachman R L. Plasminogen activator inhibitor is associated with extracellular matrix of cultured bovine smooth muscle cells. J Clin Invest 1987; 80: 1082-9.
11. Campbell I K, Last K, Novak U, Lund L R, Hamilton J A. Recombinant human interleukin-1 inhibits plasminogen activator inhibitor-1 (PAI-1) production by human articular cartilage and chondrocytes. Biochem Biophys Res Commun 1991; 174: 251-7.
12. Hamilton J A, Cheung D, Filonz E L, et al. Independent regulation of plasminogen activator inhibitor 2 and plasminogen activator inhibitor 1 in human synovial fibroblasts. Arthritis Rheum 1992; 35: 1526-34.
13. Martel-Pelletier J, Zarfarullah M, Kodama S, Pelletier J-P. In vitro effects of interleukin 1 on the synthesis of metalloproteinases, TIMP, plasminogen activators and their inhibitors in human cartilage. J Rhemnatol 1991; 18 (suppl 27): 80-4.
14. Vassalli J D, Baccino D, Belin D. A cellular binding site for the Mr 55,000 form of human urokinase plasminogen activator. J Cell Biol 1985; 100: 86-92.
15. Blasi F. Urokinase and urokinase receptor: a paracrine/ autocrine system regulating cell migration and invasiveness. Bioessays 1993; 15: 105-11.
16. Martel-Pelletier J, Faure M-P, McCollum R, Mineau F, Cloutier J-M, Pelletier J P. Plasmin, plasminogen activators and inhibitor in human osteoarthritic cartilage. J Rheumatol 1991; 18: 1863-71.
17. Kirchheimer J C, Nong Y-H, Remold H G. IFN-γ, tumour necrosis factor-α and urokinase regulate the expression of urokinase receptors on human monocytes. J Immunol 1988; 141: 4229-34.
18. Del Rosso M, Fibbi G, Magnelli L, et al. Modulation of urokinase receptors on human synovial cells and osteoarthritic chondrocytes by diacetylrhein. Int J Tissue React 1990; 12: 91-100.
19. Kirchheimer J, Remold H G, Wanivenhaus A, Binder B R. Increased proteolytic activity on the surface of monocytes from patients with rheumatoid arthritis. Arthritis Rheum 1991; 34: 1430-3.
20. Mochan E, Uhl J. Elevations in synovial fluid plasminogen activator in patients with rheumatoid arthritis. J Rheumatol 1984; 11: 123-8.
21. Kikuchi H, Tanaka S, Matsuo O. Plasminogen activator in synovial fluid from patients with rheumatoid arthritis. J Rheumatol 1987; 14: 439-45.
22. Saxne T, Lecander I, Geborek P. Plasminogen activators and plasminogen activator inhibitors in synovial fluid. Difference between inflammatory joint disorders and osteoarthritis. J Rheumatol 1993; 20: 91-6.
23. Burnett S, Hart D J, Cooper C, Spector T D. A radiographic atlas of osteoarthritis. London: Springer Verlag, 1994.
24. Arnett F C, Edworthy S M, Bloch D A, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24.
25. Doherty M, Richards N, Hornby J, Powell R. Relationship between synovial fluid C3 degradation products and local joint inflammation in rheumatoid arthritis, osteoarthritis and crystal associated arthropathy. Ann Rheum Dis 1988; 47: 190-7.
26. Roche P C, Campeau J D, Shaw S T. Comparative electrophoretic analysis of human and porcine plasminogen activators in SDS-polyacrylamide gels containing plasminogen and casein. Biochim Biophys Acta 1983; 745: 82-9.
27. Kummer J A, Abbink J J, De Boer J-P, et al. Analysis of intraarticular fibrinolytic pathways in patients with inflammatory and non-inflammatory joint diseases. Arthritis Rheum 1992; 35: 884-93.
28. Bunning R A D, Crawford A, Richardson H J, Opdennakker G, Van Damme J, Russell R G G. Interleukin 1 preferentially stimulates the production of tissue-type plasminogen activator by human articular chondrocytes. Biochim Biophys Acta 1987; 924: 473-82.
29. Levin E G. Latent tissue plasminogen activator produced by human endothelial cells in culture: evidence for an enzyme-inhibitor complex. Proc Natl Acad Sci USA 1983; 80: 6804-10.
30. Brommer E J P, Dooijewaard G, Dijkmans B A C, Breedveld F C. Plasminogen activators in synovial fluid and plasma from patients with arthritis. Ann Rheum Dis 1992; 51: 965-8.
31. Leizer T, Hamilton J A. Interleukin-1α and interleukin-1β stimulate synovial fibroblast plasminogen activator activity. Arthritis Rheum 1987; 30: 562-6.
32. Hamilton J A, Hart P H, Leizer T, Vitti G F, Campbell I K. Regulation of plasminogen activator activity in arthritic joints. J Rheumatol 1991; 18 (suppl 27): 106-9.
33. Heiple J M, Ossowski L. Human neutrophil plasminogen activator is localised in specific granules and is translocated to the cell surface by exocytosis. J Exp Med 1986; 164: 826-40.
34. Ronne E, Pappot H, Grondahl-Hansen J, et al. The receptor for urokinase plasminogen activator is present in plasma from healthy donors and elevated in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol 1995; 89: 576-81.
35. Nachman R L, Hajjar K A, Silverstein R L, Dinarello C A. Interleukin 1 induces endothelial cell synthesis of plasminogen activator inhibitor. J Exp Med 1986; 163: 1595-600.
36. Lindenhayn K, Heilmann H-H, Regling G, Haupt R. Die plasminogenaktivator-aktivitat der synovialflussigkeit als indikator fur aktivierungsphanomene bei degenerativen gelenkerkrankungen. Z Rheumatol 1989; 48: 246-53.